Astronomers Scramble To Salvage Data From Hipparcos

CAMBRIDGE, ENGLAND—Four months after their $500 million satellite failed to settle into its target orbit, European space scientists are hoping to salvage as much as half of the data that they expected to receive from the Hipparcos mission. Their optimism is based on weeks of hard work modifying the hardware and software that control the astronomical observatory to mitigate the scientific impact of the satellite’s failure to reach its proper orbit. Ironically, the reduced flow of

Written bySimon Mitton
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

CAMBRIDGE, ENGLAND—Four months after their $500 million satellite failed to settle into its target orbit, European space scientists are hoping to salvage as much as half of the data that they expected to receive from the Hipparcos mission. Their optimism is based on weeks of hard work modifying the hardware and software that control the astronomical observatory to mitigate the scientific impact of the satellite’s failure to reach its proper orbit.

Ironically, the reduced flow of information from Hipparcos has made theirjob somewhat easier. “We have less data, so what we do have we can examine more carefully,” says astronomer Floor van Leeuwen of the Royal Greenwich Observatory.

Van Leeuwen is one of more than 100 scientists from 13 nations in the European Space Agency (ESA) who have spent most of the decade preparing for the launch of Hipparcos. Its mission is to measure the position of nearly a half-million ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies